Alpine Global Management’s Mersana Therapeutics MRSN Stock Holding History

Alpine Global Management’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-401	Closed	-$40K	–	597
2022 Q1	$40K	Sell	401 -233	-37%	-$27.2K	0.01%	321
2021 Q4	$99K	Buy	+634	New	+$123K	0.01%	644
2021 Q2	–	Sell	-426	Closed	-$172K	–	344
2021 Q1	$172K	Buy	+426	New	+$207K	0.02%	260

Other funds holding MRSN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Alpine Global Management's MRSN Position: Q2 2022 in Review

Alpine Global Management sold out of Mersana Therapeutics (MRSN) in Q2 2022, closing a stake of 401 shares — an estimated $40K sold.

Alpine Global Management first reported a position in MRSN in Q1 2021 and held it in 3 quarters. The position peaked at $172K in Q1 2021. 126 funds tracked by Wall St. Rank hold MRSN as of Q2 2022.

Alpine Global Management reported no remaining Mersana Therapeutics position as of Q2 2022 after selling out during the quarter.
Alpine Global Management sold 401 Mersana Therapeutics shares in Q2 2022, an estimated $40K.
Alpine Global Management first reported a position in Mersana Therapeutics in Q1 2021 and held it in 3 quarters.
Alpine Global Management's Mersana Therapeutics position peaked at $172K in Q1 2021.
126 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2022.

Based on Alpine Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.